Just because you expect something to turn out poorly doesn't mean you're happy to be proven correct. Alzheimer's disease treatment bapineuzumab is officially dead after failing its second phase 3 trial. What does this mean for the trio of stocks involved with it -- and the one Big Pharma player with a lot riding on its version of the drug? Watch and find out.

Many investors are attracted to health care for the substantial short-term gains that positive trial results provide. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.